Amphastar Pharmaceuticals Inc

Organisation

11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Headquarters

1976

Employees

Health Technology

Industry

Jack Zhang

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Price

Target

Amphastar Pharmaceuticals Inc (AMPH) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Amphastar Pharmaceuticals Inc (AMPH) share price will touch around $29 in next 12-months.

Currently 12 wall-street analysts regularly analyze the financials of Amphastar Pharmaceuticals Inc on a frequent basis to provide recommendations along with target share price. 12 analysts offering 12-month price forecasts for Amphastar Pharmaceuticals Inc (AMPH) have a share price target of $29. This median of share price forecast represents a 59.69% upside from the latest price of $18.16 as on 15.03.26.

Amphastar Pharmaceuticals Inc (AMPH) Share Price Forecast

Home

US Stocks

Amphastar Pharmaceuticals Inc (AMPH)

Amphastar Pharmaceuticals Inc Stock Forecast

Amphastar Pharmaceuticals Inc Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Amphastar Pharmaceuticals Inc (AMPH): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Amphastar Pharmaceuticals Inc's share price and its median forecast price. As on 15.03.26, the difference is -13.45%

Amphastar Pharmaceuticals Inc Forecast and Target Price

Amphastar Pharmaceuticals Inc (AMPH) Share Price Forecast

Amphastar Pharmaceuticals Inc (AMPH) Price vs Consensus Price Target

Amphastar Pharmaceuticals Inc (AMPH) Share Price Forecast v/s Share Price Today

Amphastar Pharmaceuticals Inc (AMPH): Difference between Current Price & Median Forecasted Price

Amphastar Pharmaceuticals Inc (AMPH) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price